Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma
The value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet high-risk patients with LA-NPC have poor outcomes after chemoradiotherapy. We aimed to assess the survival benefits of induction chemotherapy in sta...
Saved in:
| Published in | PloS one Vol. 11; no. 8; p. e0160758 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
10.08.2016
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet high-risk patients with LA-NPC have poor outcomes after chemoradiotherapy. We aimed to assess the survival benefits of induction chemotherapy in stage IVa-b NPC.
A total of 602 patients with stage IVa-b NPC treated with intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy with or without induction chemotherapy were retrospectively analyzed. Overall survival (OS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, log-rank test and Cox regression analysis.
In univariate analysis, 5-year OS was 83.2% for induction chemotherapy plus concurrent chemotherapy and 74.8% for concurrent chemotherapy alone, corresponding to an absolute risk reduction of 8.4% (P = 0.022). Compared to concurrent chemotherapy alone, addition of induction chemotherapy improved 5-year DMFS (83.2% vs. 74.4%, P = 0.018) but not 5-year LRFS (83.7% vs. 83.0%, P = 0.848) or PFS (71.9% vs. 66.0%, P = 0.12). Age, T category, N category, chemotherapy strategy and clinical stage were associated with 5-year OS (P = 0.017, P = 0.031, P = 0.007, P = 0.022, P = 0.001, respectively). In multivariate analysis, induction chemotherapy plus concurrent chemotherapy was an independent favorable prognostic factor for OS (HR, 0.62; 95% CI, 0.43-0.90, P = 0.012) and DMFS (HR, 0.57; 95% CI, 0.38-0.83, P = 0.004). In subgroup analysis, induction chemotherapy significantly improved 5-year DMFS in stage IVa (86.8% vs. 77.3%, P = 0.008), but provided no significant benefit in stage IVb.
In patients with stage IVa-b NPC treated with IMRT, addition of induction chemotherapy to concurrent chemotherapy significantly improved 5-year OS and 5-year DMFS. This study provides a basis for selection of high risk patients in future clinical therapeutic trials. |
|---|---|
| AbstractList | Purpose The value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet high-risk patients with LA-NPC have poor outcomes after chemoradiotherapy. We aimed to assess the survival benefits of induction chemotherapy in stage IVa-b NPC. Patients and Methods A total of 602 patients with stage IVa-b NPC treated with intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy with or without induction chemotherapy were retrospectively analyzed. Overall survival (OS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, log-rank test and Cox regression analysis. Results In univariate analysis, 5-year OS was 83.2% for induction chemotherapy plus concurrent chemotherapy and 74.8% for concurrent chemotherapy alone, corresponding to an absolute risk reduction of 8.4% (P = 0.022). Compared to concurrent chemotherapy alone, addition of induction chemotherapy improved 5-year DMFS (83.2% vs. 74.4%, P = 0.018) but not 5-year LRFS (83.7% vs. 83.0%, P = 0.848) or PFS (71.9% vs. 66.0%, P = 0.12). Age, T category, N category, chemotherapy strategy and clinical stage were associated with 5-year OS (P = 0.017, P = 0.031, P = 0.007, P = 0.022, P = 0.001, respectively). In multivariate analysis, induction chemotherapy plus concurrent chemotherapy was an independent favorable prognostic factor for OS (HR, 0.62; 95% CI, 0.43–0.90, P = 0.012) and DMFS (HR, 0.57; 95% CI, 0.38–0.83, P = 0.004). In subgroup analysis, induction chemotherapy significantly improved 5-year DMFS in stage IVa (86.8% vs. 77.3%, P = 0.008), but provided no significant benefit in stage IVb. Conclusions In patients with stage IVa-b NPC treated with IMRT, addition of induction chemotherapy to concurrent chemotherapy significantly improved 5-year OS and 5-year DMFS. This study provides a basis for selection of high risk patients in future clinical therapeutic trials. Purpose The value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet high-risk patients with LA-NPC have poor outcomes after chemoradiotherapy. We aimed to assess the survival benefits of induction chemotherapy in stage IVa-b NPC. Patients and Methods A total of 602 patients with stage IVa-b NPC treated with intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy with or without induction chemotherapy were retrospectively analyzed. Overall survival (OS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, log-rank test and Cox regression analysis. Results In univariate analysis, 5-year OS was 83.2% for induction chemotherapy plus concurrent chemotherapy and 74.8% for concurrent chemotherapy alone, corresponding to an absolute risk reduction of 8.4% ( P = 0.022). Compared to concurrent chemotherapy alone, addition of induction chemotherapy improved 5-year DMFS (83.2% vs. 74.4%, P = 0.018) but not 5-year LRFS (83.7% vs. 83.0%, P = 0.848) or PFS (71.9% vs. 66.0%, P = 0.12). Age, T category, N category, chemotherapy strategy and clinical stage were associated with 5-year OS ( P = 0.017, P = 0.031, P = 0.007, P = 0.022, P = 0.001, respectively). In multivariate analysis, induction chemotherapy plus concurrent chemotherapy was an independent favorable prognostic factor for OS (HR, 0.62; 95% CI, 0.43–0.90, P = 0.012) and DMFS (HR, 0.57; 95% CI, 0.38–0.83, P = 0.004). In subgroup analysis, induction chemotherapy significantly improved 5-year DMFS in stage IVa (86.8% vs. 77.3%, P = 0.008), but provided no significant benefit in stage IVb. Conclusions In patients with stage IVa-b NPC treated with IMRT, addition of induction chemotherapy to concurrent chemotherapy significantly improved 5-year OS and 5-year DMFS. This study provides a basis for selection of high risk patients in future clinical therapeutic trials. The value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet high-risk patients with LA-NPC have poor outcomes after chemoradiotherapy. We aimed to assess the survival benefits of induction chemotherapy in stage IVa-b NPC. A total of 602 patients with stage IVa-b NPC treated with intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy with or without induction chemotherapy were retrospectively analyzed. Overall survival (OS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, log-rank test and Cox regression analysis. In univariate analysis, 5-year OS was 83.2% for induction chemotherapy plus concurrent chemotherapy and 74.8% for concurrent chemotherapy alone, corresponding to an absolute risk reduction of 8.4% (P = 0.022). Compared to concurrent chemotherapy alone, addition of induction chemotherapy improved 5-year DMFS (83.2% vs. 74.4%, P = 0.018) but not 5-year LRFS (83.7% vs. 83.0%, P = 0.848) or PFS (71.9% vs. 66.0%, P = 0.12). Age, T category, N category, chemotherapy strategy and clinical stage were associated with 5-year OS (P = 0.017, P = 0.031, P = 0.007, P = 0.022, P = 0.001, respectively). In multivariate analysis, induction chemotherapy plus concurrent chemotherapy was an independent favorable prognostic factor for OS (HR, 0.62; 95% CI, 0.43-0.90, P = 0.012) and DMFS (HR, 0.57; 95% CI, 0.38-0.83, P = 0.004). In subgroup analysis, induction chemotherapy significantly improved 5-year DMFS in stage IVa (86.8% vs. 77.3%, P = 0.008), but provided no significant benefit in stage IVb. In patients with stage IVa-b NPC treated with IMRT, addition of induction chemotherapy to concurrent chemotherapy significantly improved 5-year OS and 5-year DMFS. This study provides a basis for selection of high risk patients in future clinical therapeutic trials. The value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet high-risk patients with LA-NPC have poor outcomes after chemoradiotherapy. We aimed to assess the survival benefits of induction chemotherapy in stage IVa-b NPC. A total of 602 patients with stage IVa-b NPC treated with intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy with or without induction chemotherapy were retrospectively analyzed. Overall survival (OS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, log-rank test and Cox regression analysis. In univariate analysis, 5-year OS was 83.2% for induction chemotherapy plus concurrent chemotherapy and 74.8% for concurrent chemotherapy alone, corresponding to an absolute risk reduction of 8.4% (P = 0.022). Compared to concurrent chemotherapy alone, addition of induction chemotherapy improved 5-year DMFS (83.2% vs. 74.4%, P = 0.018) but not 5-year LRFS (83.7% vs. 83.0%, P = 0.848) or PFS (71.9% vs. 66.0%, P = 0.12). Age, T category, N category, chemotherapy strategy and clinical stage were associated with 5-year OS (P = 0.017, P = 0.031, P = 0.007, P = 0.022, P = 0.001, respectively). In multivariate analysis, induction chemotherapy plus concurrent chemotherapy was an independent favorable prognostic factor for OS (HR, 0.62; 95% CI, 0.43-0.90, P = 0.012) and DMFS (HR, 0.57; 95% CI, 0.38-0.83, P = 0.004). In subgroup analysis, induction chemotherapy significantly improved 5-year DMFS in stage IVa (86.8% vs. 77.3%, P = 0.008), but provided no significant benefit in stage IVb. In patients with stage IVa-b NPC treated with IMRT, addition of induction chemotherapy to concurrent chemotherapy significantly improved 5-year OS and 5-year DMFS. This study provides a basis for selection of high risk patients in future clinical therapeutic trials. The value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet high-risk patients with LA-NPC have poor outcomes after chemoradiotherapy. We aimed to assess the survival benefits of induction chemotherapy in stage IVa-b NPC.PURPOSEThe value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet high-risk patients with LA-NPC have poor outcomes after chemoradiotherapy. We aimed to assess the survival benefits of induction chemotherapy in stage IVa-b NPC.A total of 602 patients with stage IVa-b NPC treated with intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy with or without induction chemotherapy were retrospectively analyzed. Overall survival (OS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, log-rank test and Cox regression analysis.PATIENTS AND METHODSA total of 602 patients with stage IVa-b NPC treated with intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy with or without induction chemotherapy were retrospectively analyzed. Overall survival (OS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, log-rank test and Cox regression analysis.In univariate analysis, 5-year OS was 83.2% for induction chemotherapy plus concurrent chemotherapy and 74.8% for concurrent chemotherapy alone, corresponding to an absolute risk reduction of 8.4% (P = 0.022). Compared to concurrent chemotherapy alone, addition of induction chemotherapy improved 5-year DMFS (83.2% vs. 74.4%, P = 0.018) but not 5-year LRFS (83.7% vs. 83.0%, P = 0.848) or PFS (71.9% vs. 66.0%, P = 0.12). Age, T category, N category, chemotherapy strategy and clinical stage were associated with 5-year OS (P = 0.017, P = 0.031, P = 0.007, P = 0.022, P = 0.001, respectively). In multivariate analysis, induction chemotherapy plus concurrent chemotherapy was an independent favorable prognostic factor for OS (HR, 0.62; 95% CI, 0.43-0.90, P = 0.012) and DMFS (HR, 0.57; 95% CI, 0.38-0.83, P = 0.004). In subgroup analysis, induction chemotherapy significantly improved 5-year DMFS in stage IVa (86.8% vs. 77.3%, P = 0.008), but provided no significant benefit in stage IVb.RESULTSIn univariate analysis, 5-year OS was 83.2% for induction chemotherapy plus concurrent chemotherapy and 74.8% for concurrent chemotherapy alone, corresponding to an absolute risk reduction of 8.4% (P = 0.022). Compared to concurrent chemotherapy alone, addition of induction chemotherapy improved 5-year DMFS (83.2% vs. 74.4%, P = 0.018) but not 5-year LRFS (83.7% vs. 83.0%, P = 0.848) or PFS (71.9% vs. 66.0%, P = 0.12). Age, T category, N category, chemotherapy strategy and clinical stage were associated with 5-year OS (P = 0.017, P = 0.031, P = 0.007, P = 0.022, P = 0.001, respectively). In multivariate analysis, induction chemotherapy plus concurrent chemotherapy was an independent favorable prognostic factor for OS (HR, 0.62; 95% CI, 0.43-0.90, P = 0.012) and DMFS (HR, 0.57; 95% CI, 0.38-0.83, P = 0.004). In subgroup analysis, induction chemotherapy significantly improved 5-year DMFS in stage IVa (86.8% vs. 77.3%, P = 0.008), but provided no significant benefit in stage IVb.In patients with stage IVa-b NPC treated with IMRT, addition of induction chemotherapy to concurrent chemotherapy significantly improved 5-year OS and 5-year DMFS. This study provides a basis for selection of high risk patients in future clinical therapeutic trials.CONCLUSIONSIn patients with stage IVa-b NPC treated with IMRT, addition of induction chemotherapy to concurrent chemotherapy significantly improved 5-year OS and 5-year DMFS. This study provides a basis for selection of high risk patients in future clinical therapeutic trials. |
| Audience | Academic |
| Author | Su, Zhen Xie, Fang-Yun Xiao, Yao Zou, Xue-Bin Lan, Xiao-Wen Tang, Jie OuYang, Pu-Yun |
| AuthorAffiliation | 1 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong Province, People's Republic of China 2 Department of Ultrasound, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong Province, People's Republic of China University of Nebraska Medical Center, UNITED STATES |
| AuthorAffiliation_xml | – name: University of Nebraska Medical Center, UNITED STATES – name: 1 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong Province, People's Republic of China – name: 2 Department of Ultrasound, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong Province, People's Republic of China |
| Author_xml | – sequence: 1 givenname: Xiao-Wen surname: Lan fullname: Lan, Xiao-Wen – sequence: 2 givenname: Xue-Bin surname: Zou fullname: Zou, Xue-Bin – sequence: 3 givenname: Yao surname: Xiao fullname: Xiao, Yao – sequence: 4 givenname: Jie surname: Tang fullname: Tang, Jie – sequence: 5 givenname: Pu-Yun surname: OuYang fullname: OuYang, Pu-Yun – sequence: 6 givenname: Zhen surname: Su fullname: Su, Zhen – sequence: 7 givenname: Fang-Yun surname: Xie fullname: Xie, Fang-Yun |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27509025$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk1tr2zAUx83oWC_bNxibYTC2h2SSLFn2HgZd2CVQVmi2vooTXRIVR3ItOazffnKTlqSUUfxgc_z7_3V0LsfZgfNOZ9lrjMa44PjTle87B824TeExwiXirHqWHeG6IKOSoOJg5_swOw7hCiFWVGX5IjsknKEaEXaUtRc6dj60Wka71vlpcrwJNuTe5HGp81nfre0amvyrdtrYOMSnTvWJ9i6fLPXKJ6yD9ia3Lp9FWOh8egmjef4Lgm-X0N24hU76CXTSOr-Cl9lzA03Qr7bvk-zP92-_Jz9HZ-c_ppPTs5HkhMURp8bQssC10bTAClApKWVaqYrWCilZUoxUUSmAiitmOJJgKBBaz_lcSY2Lk-ztxrdtfBDbYgWBK0xYwXlVJ2K6IZSHK9F2dpWyFR6suA34biGgi1Y2WmClmEKQ8uBzagoNJSGGMGJqXhtkZPL6sj2tn690SsDFDpo90_0_zi7Fwq8FravUFp4MPmwNOn_d6xDFygapmwac9v1t3owjymryFBSTmtRsQN89QB8vxJZaQLqrdcanFOVgKk5piSgp0xwlavwIlR6lV1b6YTxSfE_wcU-QmKj_xgX0IYjp7OLp7PnlPvt-h12m6YrL4Jt-GMmwD77Zbcp9N-6mPwF0A8i0AqHT5h7BSAxLdlcuMSyZ2C5Zkn1-IJM2wnB8qoht_i_-B8_uLds |
| CitedBy_id | crossref_primary_10_1111_1754_9485_13400 crossref_primary_10_1111_ajco_13565 crossref_primary_10_1371_journal_pone_0246638 crossref_primary_10_1097_MS9_0000000000001074 crossref_primary_10_1016_j_oraloncology_2018_10_007 |
| Cites_doi | 10.1016/j.ijrobp.2014.05.555 10.5732/cjc.012.10189 10.1259/bjr.73.869.10884741 10.1016/j.ijrobp.2015.01.002 10.1016/j.radonc.2008.02.003 10.1200/JCO.2008.18.1545 10.1016/S0360-3016(00)00585-X 10.1200/JCO.2004.05.173 10.1245/s10434-010-0985-4 10.1093/jnci/dji084 10.1016/S0360-3016(03)00075-0 10.1002/cncr.28049 10.1002/cncr.29208 10.1093/jnci/djq258 10.1016/j.ijrobp.2011.11.021 10.1093/annonc/mdr116 10.1200/JCO.2005.16.790 10.1016/j.radonc.2013.10.020 10.1200/JCO.2003.06.158 10.1371/journal.pone.0067488 10.1093/annonc/mdt163 10.1016/0360-3016(78)90140-2 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2016 Public Library of Science 2016 Lan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2016 Lan et al 2016 Lan et al |
| Copyright_xml | – notice: COPYRIGHT 2016 Public Library of Science – notice: 2016 Lan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2016 Lan et al 2016 Lan et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0160758 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agriculture Science Database ProQuest Health & Medical Collection PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE MEDLINE - Academic Engineering Research Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Value of Adding Induction Chemotherapy in Stage IVa-b NPC |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1812537789 oai_doaj_org_article_1dd5d0a1da7b4f3ea622f252f979f0fc PMC4980057 4152242261 A460426932 27509025 10_1371_journal_pone_0160758 |
| Genre | Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM CGR CUY CVF ECM EIF IPNFZ NPM PJZUB PPXIY PQGLB RIG BBORY PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 5PM PUEGO - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c725t-74ff46319fe431da06c445edd849d0dc6410d38daa87d5f70caf4a249b7bdce13 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Fri Nov 26 17:13:18 EST 2021 Wed Aug 27 01:19:02 EDT 2025 Thu Aug 21 18:32:40 EDT 2025 Fri Jul 11 10:32:53 EDT 2025 Thu Jul 10 19:11:06 EDT 2025 Fri Jul 25 10:19:04 EDT 2025 Tue Jun 17 21:15:23 EDT 2025 Tue Jun 10 20:51:04 EDT 2025 Fri Jun 27 04:32:08 EDT 2025 Fri Jun 27 05:07:55 EDT 2025 Thu May 22 21:12:22 EDT 2025 Mon Jul 21 05:49:19 EDT 2025 Tue Jul 01 02:21:26 EDT 2025 Thu Apr 24 23:04:02 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c725t-74ff46319fe431da06c445edd849d0dc6410d38daa87d5f70caf4a249b7bdce13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: The authors have declared that no competing interests exist. Conceived and designed the experiments: FYX XWL XBZ.Performed the experiments: FYX XWL XBZ YX JT PYOY ZS.Analyzed the data: XWL XBZ.Contributed reagents/materials/analysis tools: XWL XBZ.Wrote the paper: FYX XWL XBZ. These authors are co-first authors on this work. |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0160758 |
| PMID | 27509025 |
| PQID | 1812537789 |
| PQPubID | 1436336 |
| PageCount | e0160758 |
| ParticipantIDs | plos_journals_1812537789 doaj_primary_oai_doaj_org_article_1dd5d0a1da7b4f3ea622f252f979f0fc pubmedcentral_primary_oai_pubmedcentral_nih_gov_4980057 proquest_miscellaneous_1815704592 proquest_miscellaneous_1811292952 proquest_journals_1812537789 gale_infotracmisc_A460426932 gale_infotracacademiconefile_A460426932 gale_incontextgauss_ISR_A460426932 gale_incontextgauss_IOV_A460426932 gale_healthsolutions_A460426932 pubmed_primary_27509025 crossref_primary_10_1371_journal_pone_0160758 crossref_citationtrail_10_1371_journal_pone_0160758 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-08-10 |
| PublicationDateYYYYMMDD | 2016-08-10 |
| PublicationDate_xml | – month: 08 year: 2016 text: 2016-08-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2016 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | X Sun (ref18) 2014; 110 SM Cao (ref1) 2011 L Chen (ref23) 2012; 84 Y Chen (ref8) 2013; 119 G Fountzilas (ref14) 2012; 23 AW Lee (ref7) 2010; 102 JC Lin (ref16) 2004 M Chua (ref25) 2014; 90 GQ Zhou (ref19) 2013; 8 T Tan (ref15) 2015; 91 MK Kam (ref5) 2003; 56 EP Hui (ref13) 2009; 27 Q Liu (ref2) 2013; 32 AW Lee (ref22) 2015; 121 X Wu (ref12) 2013; 24 RM Byers (ref24) 1978; 4 J Wee (ref6) 2005; 23 AW Lee (ref21) 2008; 87 P Xia (ref4) 2000; 48 AT Chan (ref10) 2005; 97 C Zhao (ref20) 2004; 23 DL Kwong (ref11) 2004; 22 C Nutting (ref3) 2000; 73 SB Edge (ref17) 2010; 17 JC Lin (ref9) 2003; 21 |
| References_xml | – volume: 90 start-page: S120 year: 2014 ident: ref25 article-title: Plasma EBV DNA as a Predictive Biomarker in Patients With Endemic Nasopharyngeal Carcinoma Treated With Induction Chemotherapy and Concurrent Chemoradiation Therapy publication-title: International Journal of Radiation Oncology*Biology*Physics doi: 10.1016/j.ijrobp.2014.05.555 – volume: 32 start-page: 325 year: 2013 ident: ref2 article-title: Trends in the survival of patients with nasopharyngeal carcinoma between 1976 and 2005 in Sihui, China: a population-based study publication-title: Chin J Cancer doi: 10.5732/cjc.012.10189 – volume: 73 start-page: 459 year: 2000 ident: ref3 article-title: Intensity modulated radiation therapy: a clinical review publication-title: Br J Radiol doi: 10.1259/bjr.73.869.10884741 – volume: 91 start-page: 952 year: 2015 ident: ref15 article-title: Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2015.01.002 – volume: 87 start-page: 204 year: 2008 ident: ref21 article-title: Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma publication-title: Radiother Oncol doi: 10.1016/j.radonc.2008.02.003 – volume: 27 start-page: 242 year: 2009 ident: ref13 article-title: Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.2008.18.1545 – volume: 48 start-page: 329 year: 2000 ident: ref4 article-title: Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(00)00585-X – volume: 22 start-page: 2643 year: 2004 ident: ref11 article-title: Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study publication-title: J Clin Oncol doi: 10.1200/JCO.2004.05.173 – volume: 17 start-page: 1471 year: 2010 ident: ref17 article-title: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM publication-title: Ann Surg Oncol doi: 10.1245/s10434-010-0985-4 – volume: 97 start-page: 536 year: 2005 ident: ref10 article-title: Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji084 – volume: 56 start-page: 145 year: 2003 ident: ref5 article-title: Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(03)00075-0 – start-page: 114 year: 2011 ident: ref1 article-title: The prevalence and prevention of nasopharyngeal carcinoma in China publication-title: The prevalence and prevention of nasopharyngeal carcinoma in China – start-page: 156 year: 2004 ident: ref16 article-title: Another way to estimate outcome of advanced nasopharyngeal carcinoma—is concurrent chemoradiotherapy adequate? publication-title: Another way to estimate outcome of advanced nasopharyngeal carcinoma—is concurrent chemoradiotherapy adequate? – volume: 119 start-page: 2230 year: 2013 ident: ref8 article-title: Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China publication-title: Cancer doi: 10.1002/cncr.28049 – volume: 121 start-page: 1328 year: 2015 ident: ref22 article-title: Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma publication-title: Cancer doi: 10.1002/cncr.29208 – volume: 102 start-page: 1188 year: 2010 ident: ref7 article-title: Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djq258 – volume: 84 start-page: 196 year: 2012 ident: ref23 article-title: Prognostic value of subclassification using MRI in the t4 classification nasopharyngeal carcinoma intensity-modulated radiotherapy treatment publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2011.11.021 – volume: 23 start-page: 427 year: 2012 ident: ref14 article-title: Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation publication-title: Ann Oncol doi: 10.1093/annonc/mdr116 – volume: 23 start-page: 6730 year: 2005 ident: ref6 article-title: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety publication-title: J Clin Oncol doi: 10.1200/JCO.2005.16.790 – volume: 110 start-page: 398 year: 2014 ident: ref18 article-title: Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities publication-title: Radiother Oncol doi: 10.1016/j.radonc.2013.10.020 – volume: 21 start-page: 631 year: 2003 ident: ref9 article-title: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival publication-title: J Clin Oncol doi: 10.1200/JCO.2003.06.158 – volume: 8 start-page: e67488 year: 2013 ident: ref19 article-title: Radiation-induced temporal lobe injury for nasopharyngeal carcinoma: a comparison of intensity-modulated radiotherapy and conventional two-dimensional radiotherapy publication-title: PLoS One doi: 10.1371/journal.pone.0067488 – volume: 24 start-page: 2131 year: 2013 ident: ref12 article-title: Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma publication-title: Ann Oncol doi: 10.1093/annonc/mdt163 – volume: 23 start-page: 1532 year: 2004 ident: ref20 article-title: Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma publication-title: Ai Zheng – volume: 4 start-page: 215 year: 1978 ident: ref24 article-title: The therapeutic and prognostic implications of nerve invasion in cancer of the lower lip publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/0360-3016(78)90140-2 |
| SSID | ssj0053866 |
| Score | 2.2555957 |
| Snippet | The value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet... Purpose The value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet... PURPOSE:The value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet... Purpose The value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0160758 |
| SubjectTerms | Adolescent Adult Aged Analysis Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biopsy Cancer therapies Carcinoma - drug therapy Carcinoma - mortality Carcinoma - pathology Carcinoma - radiotherapy Care and treatment Chemoradiotherapy Chemotherapy Cisplatin - administration & dosage Clinical trials Diagnosis Disease control Disease-Free Survival Family medical history Female Health aspects Humans Induction Chemotherapy Intensity-modulated radiotherapy Kaplan-Meier Estimate Laboratories Male Medical imaging Medical prognosis Medicine and Health Sciences Metastases Metastasis Middle Aged Multivariate analysis Nasopharyngeal cancer Nasopharyngeal Carcinoma Nasopharyngeal Neoplasms - drug therapy Nasopharyngeal Neoplasms - mortality Nasopharyngeal Neoplasms - pathology Nasopharyngeal Neoplasms - radiotherapy NMR Nuclear magnetic resonance Oncology Organoplatinum Compounds - administration & dosage Patient outcomes Patients Physical Sciences Radiation Radiation therapy Radiotherapy, Intensity-Modulated Regression analysis Research and Analysis Methods Retrospective Studies Risk Risk factors Risk groups Risk reduction Survival Test procedures Throat cancer Treatment Outcome Ultrasonic imaging |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQ5dWFAgYhAYe0TmzHybGtqFoORWpp1Vvk-LFdqSSrfRz675lxnGiDKsqB28r-HG1mxuOxMvMNIZ-MN1L71CalNy4RksMvbkxSaJWzrK557UKW71l-cim-X8vrjVZfmBPW0QN3gttPrZWW6dRqVQvPnc6zzGcy86UqPfMGvS-cef1lqvPBsIvzPBbKcZXuR73szdvG7QVONWzxvnEQBb7-wStvzW_b5X0h55-ZkxtH0fFT8iTGkPSg--_b5JFrnpHtuEuX9Eukkv76nMzP3WrR9tWUtGcgoa2nEPjRizU4CjA1eggr_GyF49jLI9Q6UOQSiPVZd3TWUIhLp46eXumkpmca2x_oxV0zhUiTHmFHoqb9pV-Qy-NvP49OkthjITEqk6tECe9FDvvQOwglrGa5EUI6awtRWmZNLlJmeWG1LpSVXjGjvdBwZ6tVDVJI-Uuy1YBUdwhNTclqkbOacS0YL3QptdWgCJPZtObFhPBe4JWJBOTYB-O2Cl_VFFxEOvlVqKYqqmlCkmHVvCPgeAB_iLocsEifHQbAqKpoVNVDRjUh79ESqq4WdXAC1QG8Htb-8mxCPgYEUmg0mKMz1evlsjr9cfUPoIvzEehzBPkWxGF0rItoUfEwvoncHSHBEZjR9A7abS-VZYXBm-RKFSWs7G35_ukPwzQ-FPPuGteuAwYCwqyU2V8xUsHNoATMq257DNLH7gH4IXtC1GjjjNQznmlmN4HlXJQFVkq__h_6fEMeQ6CbJ4HKeJdsrRZr9xaCyVX9LviN3xWqdmw priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELagvPCCGL9WGGAQEvCQzYntOHlC20TZeBjSxqa9RY4dl0ojKU37sP-eO9cJDZoGb5X9OWrufOdz7PuOkHfGGaldbKPcmSoSksMvbkyUaZWypCx5Wflbvifp0bn4eikvwwe3Nlyr7Hyid9S2MfiNfA9XIsmVyvJP818RVo3C09VQQuMuuRfDSoNXurLJl84Tgy2naUiX4yreC9rZnTd1teuZ1bDQ-8Zy5Fn7e988ml817U2B59_3JzcWpMlD8iBEknR_rfotcqeqH5GtYKst_RAIpT8-JvPTarloupxK2vGQ0MZRCP_o2QrcBUw4egAj3GyJ7VjRw2c8UGQUCFla13RWU4hOpxU9vtBRSU80FkHQi-t6CvEmPcS6RHXzUz8h55PP3w-PolBpITIqkctICedECtboKggorGapEUJW1mYit8yaVMTM8sxqnSkrnWJGO6Fh51aqEqQQ86dkVINUtwmNTc5KkbKScS0Yz3QutdWgCJPYuOTZmPBO4IUJNORYDeOq8GdrCrYja_kVqKYiqGlMon7UfE3D8Q_8AeqyxyKJtm9oFtMi2GQRWyst0_C-qhSOVzpNEpfIxOUqd8yZMXmNM6FYZ6T2rqDYh9fDDGCejMlbj0AijRpv6kz1qm2L428X_wE6Ox2A3geQa0AcRofsiAYVD-2byJ0BEtyBGXRv47ztpNIWfwwHRnZz-ebuN303PhRv39VVs_IYCAuTXCa3YqSC_UEOmGdr8-iljzUE8Dh7TNTAcAbqGfbUsx-e61zkGeZLP7_9r78g9yGQTSNPVbxDRsvFqnoJweKyfOU9wm8ClmzS priority: 102 providerName: ProQuest |
| Title | Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27509025 https://www.proquest.com/docview/1812537789 https://www.proquest.com/docview/1811292952 https://www.proquest.com/docview/1815704592 https://pubmed.ncbi.nlm.nih.gov/PMC4980057 https://doaj.org/article/1dd5d0a1da7b4f3ea622f252f979f0fc http://dx.doi.org/10.1371/journal.pone.0160758 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZ2uxcuiOW1haUYhAQcUuVhx8kBoW3VsotEQV266i1y7LisVJLSh0Qv_HZm3CTaoPI4cLEi-3OkzHjscez5hpAXyigujaed2KjMYTyAp0ApJ5IidP00DdLM3vIdhecT9n7KpwekytlaCnC1d2uH-aQmy3n3-7ftWzD4NzZrg_CqTt1FkWddy5jGo0NyBGuTwJwGH1h9rgDWHYZlAN3vejYWKMvjX8_WrcW8WO1zRX-9UXljiRreIbdL35Ke7QbDMTnI8rvkuLTeFX1VUky_vkcW42y9LKooS1oxk9DCUHAI6eUGJhAYgrQHPcz1Gusxx4eNgaDIMVDGbW3pdU7BX51l9OJKOikdSUyLIJfbfAYeKO1jpqK8-Crvk8lw8Ll_7pS5FxwlfL52BDOGhWCfJgMXQ0s3VIzxTOuIxdrVKmSeq4NISxkJzY1wlTRMwl4uFSlIwQsekFYOUj0h1FOxm7LQTd1AMjeIZMyllqAI5WsvDaI2CSqBJ6okJsf8GPPEnrYJ2KDs5JegmpJSTW3i1L0WO2KOv-B7qMsai7TatqJYzpLSShNPa65dCd8rUmaCTIa-b3zum1jExjWqTZ7iSEh2Mar15JCcwedhTHDgt8lzi0BqjRzv7szkZrVKLj5e_QPoctwAvSxBpgBxKFnGSxSoeKi_iTxtIGGCUI3mExy3lVRWCTp1PBAiiqFnNZb3Nz-rm_GleB8vz4qNxYCj6Mfc_yOGC9gxxIB5uDOPWvqYVQAPuNtENAynoZ5mS379xbKfszjCCOpH_0Ofj8ktcIBDx1Icn5LWernJnoCTuU475FBMBZRR38Ny-K5DjnqD0adxx_626dh5Bcsfg5-fkYaI |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKcoALory6UKhBIOCQNomdODkg1BaWLi2L1Jd6Sx0_lpVKsuxDaP8Uv5GZvNigqnDpbWWPo83M-JtxPA9CXiqrAmk97cRWGYcHDH4xpZxIitD105SlpojyHYR7J_zzWXC2Qn7VuTAYVlljYgHUOlf4jXwLLVHAhIji9-MfDnaNwtvVuoVGqRb7ZvETjmzTd_0PIN9Xvt_7eLy751RdBRwl_GDmCG4tD0HzrAHjqaUbKs4Do3XEY-1qFXLP1SzSUkZCB1a4Slou4ZSSilQr4zF47g1ykzOw5JiZ3vtUIz9gRxhW6XlMeFuVNmyO88xsFpXcsLH8kvkrugQ0tqAzvsinlzm6f8drLhnA3l1yp_Jc6XapaqtkxWT3yGqFDVP6pipg_fY-GR-a2SSvczhpXfeE5paCu0mP5gBPoOB0B1bY0QzHsYNIkWFBsYJBlRW2oKOMgjc8NLR_Kp2UDiQ2XZCTRTYE_5buYh-kLP8uH5CTa5HBQ9LJgKtrhHoqdlMeuqnLJHdZJONAagmCUL72UhZ1CasZnqiq7Dl237hIirs8Acefkn8JiimpxNQlTrNqXJb9-Af9DsqyocWi3cVAPhkmFQYkntaBdiW8r0i5ZUaGvm_9wLexiK1rVZdsoCYkZQZsAz3JNrweZhwzv0teFBRYuCPDyKChnE-nSf_r6X8QHR22iF5XRDYHdihZZWPkKHgYX6Zcb1EC_KjW9Brqbc2VafJno8LKWpcvn37eTONDMdovM_m8oAE31I8D_0qaQMB5JAaaR-X2aLiPPQvw-rxLRGvjtMTTnslG34ra6jyOMD_78dV_fYPc2jv-cpAc9Af7T8htcKJDpyiTvE46s8ncPAVHdZY-K9CBkvPrhqPf6v2rAA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGkRAviHFbYTCDQMBD1iR24uQBoa1jWhkqaGPT3jLHl1JpJKUXof41fh3npE5o0TR42Vtlf46ac_NxfC6EvFRWRdIG2kutMh6PGPxiSnmJFLEf5jnLTRXl248PTvjHs-hsjfyqc2EwrLK2iZWh1qXCb-Qd3IkiJkSSdqwLi_iyt_9-9MPDDlJ401q301iIyKGZ_4Tj2-Rdbw94_SoM9z987R54rsOAp0QYTT3BreUxSKE1sJFq6ceK88honfBU-1rFPPA1S7SUidCRFb6Slks4seQi18oEDJ57g9wUTCSoY0m3CS8BOxLHLlWPiaDjJGN7VBZmu6rqhk3ml7bCqmNAsy-0Rhfl5DKn9-_YzaXNcP8uueO8WLqzELt1smaKe2Td2YkJfeOKWb-9T0ZHZjou63xOWtdAoaWl4HrS4xmYKhB2ugsr7HCK49hNpMq2oFjNwGWIzemwoOAZDwztnUovp32JDRjkeF4MwNelXeyJVJTf5QNyci08eEhaBVB1g9BApX7OYz_3meQ-S2QaSS2BESrUQc6SNmE1wTPlSqBjJ46LrLrXE3AUWtAvQzZljk1t4jWrRosSIP_A7yIvGywW8K4GyvEgc_YgC7SOtC_hfUXOLTMyDkMbRqFNRWp9q9pkCyUhW2TDNmYo24HXw-xjFrbJiwqBRTwKVIeBnE0mWe_z6X-Ajo9WQK8dyJZADiVdZkaJjIfxZeTmChJMkVqZ3kC5rakyyf4oLaysZfny6efNND4UI_8KU84qDLikYRqFV2IiAWeTFDCPFurRUB_7F-BVepuIFcVZYc_qTDH8VtVZ52mCudqPr_7rW-QWGKLsU69_-ITcBn869qqKyZukNR3PzFPwWaf5s8o4UHJ-3dboN0mYrwE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Retrospective+Analysis+of+the+Survival+Benefit+of+Induction+Chemotherapy+in+Stage+IVa-b+Nasopharyngeal+Carcinoma&rft.jtitle=PloS+one&rft.au=Xiao-Wen+Lan&rft.au=Xue-Bin+Zou&rft.au=Yao+Xiao&rft.au=Jie+Tang&rft.date=2016-08-10&rft.pub=Public+Library+of+Science+%28PLoS%29&rft.eissn=1932-6203&rft.volume=11&rft.issue=8&rft.spage=e0160758&rft_id=info:doi/10.1371%2Fjournal.pone.0160758&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1dd5d0a1da7b4f3ea622f252f979f0fc |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |